Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Trainor

Plastic Surgery within the Head & Neck Gilbert, AZ Doctor of Osteopathy

NPI 1942292024 CMS profile 589306

3420 S Mercy Rd, Ste 107, Gilbert, AZ 85297

Open in the dashboard

General payments

$2,804

23 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Trainor of Gilbert, AZ is reported in the CMS Open Payments database as having received $2,804 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Plastic Surgery within the Head & Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $523 4
2024 General $236 3
2023 General $305 2
2022 General $208 3
2021 General $1,248 7
2020 General $17 1
2019 General $267 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Trainor
  • Plastic Surgery within the Head & Neck median
  • Middle half of Plastic Surgery within the Head & Neck
  • National median

In program year 2025, general payments to Brian Trainor were reported at $523. Among 399 Plastic Surgery within the Head & Neck profiles paid that year, the median was $237 and the middle half received between $103 and $520.

Show as a table
Year Brian Trainor Plastic Surgery within the Head & Neck median Middle half National median
2019 $267 $200 $82–$550 $163
2020 $17 $120 $46–$330 $114
2021 $1,248 $166 $60–$382 $132
2022 $208 $208 $83–$530 $149
2023 $305 $202 $77–$538 $160
2024 $236 $260 $99–$645 $164
2025 $523 $237 $103–$520 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $949 2 payments
  2. Aerin Medical Inc. $612 5 payments
  3. Stryker Corporation $547 5 payments
  4. Intersect ENT, Inc. $417 4 payments
  5. Acclarent, Inc $134 3 payments
  6. Olympus America Inc. $90 1 payment
  7. HeartFlow, Inc. $26 1 payment
  8. Lucid Diagnostics Inc. $19 1 payment
  9. Acell, Inc. $10 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,886 22 payments
  2. Travel and Lodging $918 1 payment
Products named General payments · program years 2019–2025
  1. VIVAER STYLUS $612 5 payments
  2. RHINAER STYLUS $612 5 payments
  3. PROPEL $276 2 payments
  4. XPRESS ENT DILATION SYSTEM $211 3 payments
  5. CLARIFIX $175 1 payment
  6. MEDLINE INDUSTRIES, INC. $161 1 payment
  7. SINUVA $142 2 payments
  8. TruDi NAV Cable $115 1 payment
  9. FFRct $26 1 payment
  10. Relieva Spinplus $14 1 payment
  11. Other $4 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

367

Median for Otolaryngology: 297

Drug cost

$4,575

Median for Otolaryngology: $6,314

Branded share of claims

12.5%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Esomeprazole Magnesium Generic 29 $1,948
Montelukast Sodium Generic 54 $575
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 32 $439
Oxycodone Hcl Generic 51 $413
Cefdinir Generic 18 $391
Cephalexin Generic 16 $213
Ssd Silver Sulfadiazine Brand 14 $117
Levothyroxine Sodium Generic 20 $100
Prednisone Generic 47 $90
Amoxicillin Generic 26 $89

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$108,233

Medicare's payments for the services billed

Medicare patients

153

Average age 75

Services billed

846

74 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 31%
Diabetes 29%
Chronic kidney disease 27%
Depression 27%
COPD 23%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery within the Head & Neck in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record